PhRMA: U.S. R&D pipeline includes 452 drugs for rare diseases

10/11/2013 | PharmaTimes (U.K.)

PhRMA reported that 452 new treatments for rare diseases are being developed by U.S. biopharmaceutical research firms. The drugs and vaccines, either under review by the FDA or in human clinical trials, include treatments for autoimmune disorders, infectious diseases, neurological conditions and genetic disorders. The FDA has said that 1 in 3 new drug approvals in the past five years has been for a rare disease.

View Full Article in:

PharmaTimes (U.K.)